Conclusion and Results:
The patient’s history of anaphylaxis to Rituximab and steroid dependence post-Tocilizumab complicates the management of her condition, highlighting the need for alternative therapeutic strategies. It is to note that she has not experienced any articular pain, which is strikingly unusual in a known Still’s disease patient. With our patient, we had no option but to resume steroid therapy, as there is no data on any other forms of treatment. The patient will also be given a new trial of rituximab since other treatment options are very limited.